The retrospective, observational, multicenter study included 141 patients, 96 with ulcerative colitis and 45 with Crohn disease, at 14 centers in Italy.
Since CT-P13 (Inflectra, Remsima), an infliximab biosimilar referencing Remicade, was authorized for use in Europe, numerous studies have investigated the safety and efficacy of the biosimilar in the inflammatory bowel disease (IBD) population. Now, a study of a large outpatient cohort with IBD in Italian primary centers has added to the growing body of data on the long-term efficacy and safety of the biosimilar.
The retrospective, observational, multicenter study included 141 patients, 96 with ulcerative colitis (UC) and 45 with Crohn disease (CD), at 14 centers. The patients initiated the biosimilar between 2015 and 2017. Most of the patients were naïve to anti—tumor necrosis factor (anti-TNF) agents (26% in the UC group and 28.9% in the CD group had previous anti-TNF exposure, and most were given the biosimilar after a loss of response to another anti-TNF).
Patients received CT-P13 at 5 mg/kg via infusion at weeks 0, 2, and 6, and then every 8 weeks thereafter. Dose escalation was used when necessary to maintain remission.
During a median follow-up of 24 (range, 6-24) months, remission, as assessed by Mayo score in the UC group and by the Harvey-Bradshaw Index in the CD group, was achieved by 57.3% of patients in the UC group and 75.6% of patients in the CD group.
Among patients who had previous anti-TNF exposure, 48.0% of patients with UC and 61.5% of patients with CD achieved remission.
Mucosal healing was observed in 75% of the UC group and 84.2% of the CD group, and 96.9% and 97.8% of patients in the respective groups were able to reduce their dose of steroids. In total, 2.1% and 6.7% of patients in each group went on to have IBD-related surgery during the follow-up period.
Only 1 adverse event was reported: A skin reaction occurred in a patient at the time of infusion, leading to an interruption of treatment.
According to the authors, this first Italian study to include a follow-up of 24 months shows the biosimilar’s efficacy and safety in the primary, outpatient IBD setting. Longer-term studies, they add, will be needed to assess switching from the reference to the biosimilar.
Reference
Tursi A, Mocci G, Faggiani R, et al. Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life, multicenter, observational study in Italian primary inflammatory bowel disease centers. Ann Gastroenterol. 2019;21(4):392-399. doi: 10.20524/aog.2019.0377.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.